Trials / Recruiting
RecruitingNCT07274085
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) Characteristics, and Preliminary Antitumor Efficacy of HDM2017 in Participants With Advanced Malignant Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I clinical study. All subjects are patients with advanced solid tumors. The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor efficacy of HDM2017 in patients with advanced malignant solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HDM2017 | Participants will be treated with HDM2017 intravenous infusion |
Timeline
- Start date
- 2025-11-18
- Primary completion
- 2026-12-31
- Completion
- 2027-07-01
- First posted
- 2025-12-10
- Last updated
- 2025-12-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07274085. Inclusion in this directory is not an endorsement.